Shanghai Allist Pharmaceuticals Completes Board Reelection, Du Jinhao Appointed as Chairman and General Manager

Deep News11-27

Shanghai Allist Pharmaceuticals Co.,Ltd. (688578) announced that it held the first meeting of its third board of directors on November 27, 2025, electing the chairman, vice chairman, and members of various specialized committees. Senior management and securities affairs representatives were also appointed.

The board members include non-independent directors Du Jinhao (Chairman), Qi Ju, Hu Jie, Xu Feng, and Xu Cong, as well as independent directors Zhu Chafen, Li Hanjie, and Li Chengzhang. Employee representative director Chu Shengming was also appointed, with all terms lasting three years from the date of approval by the shareholders' meeting.

Regarding senior management appointments, Du Jinhao was appointed as General Manager, while Hu Jie and Xu Feng were named Executive Deputy General Managers. Shan Huafeng and Huang Chen were appointed as Deputy General Managers, Li Shuo as Board Secretary, Wang Lin as Chief Financial Officer and Financial Head, and Wang Shuwen as Securities Affairs Representative.

In the first three quarters of 2025, Shanghai Allist Pharmaceuticals reported revenue of 3.733 billion yuan and net profit attributable to shareholders of 1.616 billion yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155049531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155049531","market":"fut","top_or_hot":-1,"title":"Shanghai Allist Pharmaceuticals Completes Board Reelection, Du Jinhao Appointed as Chairman and General Manager","media":"Deep News","content":"<p>Shanghai Allist Pharmaceuticals Co.,Ltd. (688578) announced that it held the first meeting of its third board of directors on November 27, 2025, electing the chairman, vice chairman, and members of various specialized committees. Senior management and securities affairs representatives were also appointed.</p>\n<p>The board members include non-independent directors Du Jinhao (Chairman), Qi Ju, Hu Jie, Xu Feng, and Xu Cong, as well as independent directors Zhu Chafen, Li Hanjie, and Li Chengzhang. Employee representative director Chu Shengming was also appointed, with all terms lasting three years from the date of approval by the shareholders' meeting.</p>\n<p>Regarding senior management appointments, Du Jinhao was appointed as General Manager, while Hu Jie and Xu Feng were named Executive Deputy General Managers. Shan Huafeng and Huang Chen were appointed as Deputy General Managers, Li Shuo as Board Secretary, Wang Lin as Chief Financial Officer and Financial Head, and Wang Shuwen as Securities Affairs Representative.</p>\n<p>In the first three quarters of 2025, Shanghai Allist Pharmaceuticals reported revenue of 3.733 billion yuan and net profit attributable to shareholders of 1.616 billion yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Allist Pharmaceuticals Completes Board Reelection, Du Jinhao Appointed as Chairman and General Manager</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Allist Pharmaceuticals Completes Board Reelection, Du Jinhao Appointed as Chairman and General Manager\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-27 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Allist Pharmaceuticals Co.,Ltd. (688578) announced that it held the first meeting of its third board of directors on November 27, 2025, electing the chairman, vice chairman, and members of various specialized committees. Senior management and securities affairs representatives were also appointed.</p>\n<p>The board members include non-independent directors Du Jinhao (Chairman), Qi Ju, Hu Jie, Xu Feng, and Xu Cong, as well as independent directors Zhu Chafen, Li Hanjie, and Li Chengzhang. Employee representative director Chu Shengming was also appointed, with all terms lasting three years from the date of approval by the shareholders' meeting.</p>\n<p>Regarding senior management appointments, Du Jinhao was appointed as General Manager, while Hu Jie and Xu Feng were named Executive Deputy General Managers. Shan Huafeng and Huang Chen were appointed as Deputy General Managers, Li Shuo as Board Secretary, Wang Lin as Chief Financial Officer and Financial Head, and Wang Shuwen as Securities Affairs Representative.</p>\n<p>In the first three quarters of 2025, Shanghai Allist Pharmaceuticals reported revenue of 3.733 billion yuan and net profit attributable to shareholders of 1.616 billion yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688578","symbol_name":"艾力斯","start_time":0,"source_url":"","article_id":"1155049531","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155049531","pubTimestamp":1764249700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shanghai Allist Pharmaceuticals Co.,Ltd. (688578) announced that it held the first meeting of its third board of directors on November 27, 2025, electing the chairman, vice chairman, and members of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688578":"艾力斯","BK0239":"医药制造"},"translate_title":"上海艾利斯特制药完成董事会换届杜金浩任董事长兼总经理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688578":1},"content_text":"Shanghai Allist Pharmaceuticals Co.,Ltd. (688578) announced that it held the first meeting of its third board of directors on November 27, 2025, electing the chairman, vice chairman, and members of various specialized committees. Senior management and securities affairs representatives were also appointed.\nThe board members include non-independent directors Du Jinhao (Chairman), Qi Ju, Hu Jie, Xu Feng, and Xu Cong, as well as independent directors Zhu Chafen, Li Hanjie, and Li Chengzhang. Employee representative director Chu Shengming was also appointed, with all terms lasting three years from the date of approval by the shareholders' meeting.\nRegarding senior management appointments, Du Jinhao was appointed as General Manager, while Hu Jie and Xu Feng were named Executive Deputy General Managers. Shan Huafeng and Huang Chen were appointed as Deputy General Managers, Li Shuo as Board Secretary, Wang Lin as Chief Financial Officer and Financial Head, and Wang Shuwen as Securities Affairs Representative.\nIn the first three quarters of 2025, Shanghai Allist Pharmaceuticals reported revenue of 3.733 billion yuan and net profit attributable to shareholders of 1.616 billion yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155049531","isCrawlerRequest":true}